Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study (PREDICT)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
- This International-European, investigator-initiated, multicenter, prospective, observational study will be performed in centers that belong to the European Foundation for the Study of Chronic Liver failure (EF-CLIF)-European Association for Study of the Liver (EASL)-EASL-CLIF Consortium.
- The population of patients would include ca. 1,200 cirrhotic patients over a twelve-months period. These patients will be admitted/referred to the study center because of acute decompensation (AD) of cirrhosis (ascites, overt encephalopathy, GI-hemorrhage, new onset of non-obstructive jaundice and/or bacterial infections), without ACLF (as defined according to the Canonic study ) at hospitalization.
- After the enrolment visit, the patients will be stratified into two groups: Group 1 patients with high risk of ACLF development (CLIF-C AD score ≥ 50) and in Group 2 patients with low risk of ACLF (CLIF-C AD score <50). The whole cohort will be followed for 3 months, while Group 1 will be followed more closely. Development of ACLF is an end-point and in this case a final visit 7-10 days after ACLF development is planned. Data on liver transplantation, mortality and causes of mortality 3 months, 6 months and 12 months will be collected in the whole cohort.
- Prospective collection of biological material and performance of ancillary studies investigating predictors for development and pathogenesis of ACLF.
Specific goals of the study:
- To identify early clinical predictors, biomarkers, mechanisms and precipitating events during the critical period prior to and involved in the development and clinical course of ACLF (with special emphasis to medical trajectory and drug history) in patients admitted/referred to study center with acute decompensation of cirrhosis (ascites, GI-hemorrhage, overt encephalopathy, new onset of non-obstructive jaundice and/or bacterial infections) and the chronological relationship of the events with occurrence and dynamics of ACLF development.
- To develop a score predicting ACLF development (CLIF-PREDICT score) and assess 28-day, 90-day, 6-month and 1-year all-cause mortality in cirrhotic patients with acute AD, but without ACLF.
- To serve as a core (hub) study for prospective ancillary studies regarding diagnosis, prognosis and pathogenesis of AD and ACLF.
Main endpoints
Assessment of the critical period prior to ACLF development
- Characterization of mechanisms responsible for ACLF development
- Predictors of clinical course dynamics of ACLF evolution and mortality.
- Identification and role of precipitating events for ACLF development.
- To elaborate a CLIF-PREDICT score 2. Secondary endpoints
- Prospective core ancillary studies to investigate the pathogenesis of ACLF.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Graz, Austria
- Medical University Graz
-
Innsbruck, Austria
- Medical University of Innsbruck
-
Vienna, Austria
- Medical University of Vienna
-
-
-
-
-
Antwerp, Belgium
- University Hospital Antwerp
-
Brussels, Belgium
- C.U.B Erasmo
-
Ghent, Belgium
- Ghent University Hospital
-
Leuven, Belgium
- University Hospital Leuven
-
-
-
-
-
Aarhus, Denmark
- Aarhus University Hospital
-
Copenhagen, Denmark
- Hvidovre University Hospital
-
-
-
-
-
Bondy, France
- Hospital Jean Verdier
-
Paris, France
- Hopital Beaujon
-
Paris, France
- Hôpital Paul Brousse
-
-
-
-
-
Aachen, Germany
- RTWH Aachen
-
Bonn, Germany
- University Hospital Bonn
-
Frankfurt am Main, Germany
- JW Goethe University Hospital
-
Halle, Germany
- University Hospital Halle-Wittenberg
-
Hannover, Germany
- Hannover Medical School
-
Jena, Germany
- University Hospital Jena
-
Leipzig, Germany
- University Hospital Leipzig
-
Munich, Germany
- University hospital Munich LMU
-
-
-
-
-
Debrecen, Hungary
- University of Debrecen
-
-
-
-
-
Bologna, Italy
- University of Bologna
-
Brindisi, Italy
- Internal Medicine PO Ostuni
-
Padova, Italy
- University Clinic Padova
-
Rome, Italy
- Università Sapienza
-
Torino, Italy
- A.O.U. Torino
-
-
-
-
-
Leiden, Netherlands
- Leiden University Medical Center
-
-
-
-
-
Vila Real, Portugal
- CHTMAD Vila Real
-
-
-
-
-
Kosice, Slovakia
- Pavol Jozef Sfarik University Kosice/Roosevelt Hospital Bystrica
-
-
-
-
-
Barcelona, Spain
- Hospital de Sant Pau
-
Barcelona, Spain
- Hospital Universitari Vall d´Hebrón
-
Barcelona, Spain
- Hospital Clinic y Provencial de Barcelona
-
Madrid, Spain
- Hospital General Universitario Gregorio Marañón
-
Madrid, Spain
- Hospital Ramon y Cajal
-
Sevilla, Spain
- Virgen del Rocio
-
-
-
-
-
Bern, Switzerland
- Inselspital
-
Geneva, Switzerland
- Hôpitaux Universitaires Genève
-
St. Gallen, Switzerland
- Cantonal Hospital St. Gallen
-
-
-
-
-
Istanbul, Turkey
- Marsara University
-
-
-
-
-
Birmingham, United Kingdom
- Birmingham University Hospitals
-
London, United Kingdom
- Royal Free Hospital
-
London, United Kingdom
- Imperial College
-
London, United Kingdom
- King´s College
-
Nottingham, United Kingdom
- Nottingham University Hospitals
-
Plymouth, United Kingdom
- Derriford Hospital, Plymouth Hospitals Trust
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
The patients admitted/referred to study center with AD of cirrhosis (ascites, overt encephalopathy, new onset of non-obstructive jaundice, GI-hemorrhage and/or bacterial infections), but without ACLF (as defined according to the CANONIC study) at study inclusion.
Exclusion Criteria:
- Presence of ACLF at inclusion;
- Pregnancy;
- Age <18 years;
- Patients with acute or subacute liver failure without underlying cirrhosis;
- Patients with cirrhosis who develop decompensation in the postoperative period following partial hepatectomy;
- Evidence of current malignancy except for non-melanocytic skin cancer and hepatocellular carcinoma within Milan criteria;
- Presence or history of severe extra-hepatic diseases (e.g., chronic renal failure requiring hemodialysis, severe heart disease (NYHA > II); severe chronic pulmonary disease (GOLD > III), severe neurological and psychiatric disorders);
- HIV-positive patients
- Previous liver or other transplantation
- Admission/referral of more than 72 hours before inclusion
- Patients who decline to participate or who cannot provide prior written informed consent and when there is documented evidence that the patient has no legal surrogate decision maker and it appears unlikely that the patient will regain consciousness or sufficient ability to provide delayed informed consent;
- Physician´s denial (e.g. the investigator considers that the patient will not follow the protocol scheduled).
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group 1
Group 1 patients with high risk of ACLF development (CLIF-C AD score ≥ 50)
|
The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.
|
|
Group 2
Group 2 patients with low risk of ACLF (CLIF-C AD score <50)
|
The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.
|
|
ACLF
ACLF-patients were specified the patients who were admitted at hospital with ACLF,
|
The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients developing ACLF within 12 weeks and severity of ACLF development
Time Frame: 12 weeks
|
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Score to PREDICT ACLF
Time Frame: 12 weeks
|
-Calculate a Score to predict ACLF
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, Giovo I, Uschner FE, Jansen C, Jimenez C, Mookerjee R, Gustot T, Albillos A, Bañares R, Jarcuska P, Steib C, Reiberger T, Acevedo J, Gatti P, Shawcross DL, Zeuzem S, Zipprich A, Piano S, Berg T, Bruns T, Danielsen KV, Coenraad M, Merli M, Stauber R, Zoller H, Ramos JP, Solé C, Soriano G, de Gottardi A, Gronbaek H, Saliba F, Trautwein C, Kani HT, Francque S, Ryder S, Nahon P, Romero-Gomez M, Van Vlierberghe H, Francoz C, Manns M, Garcia-Lopez E, Tufoni M, Amoros A, Pavesi M, Sanchez C, Praktiknjo M, Curto A, Pitarch C, Putignano A, Moreno E, Bernal W, Aguilar F, Clària J, Ponzo P, Vitalis Z, Zaccherini G, Balogh B, Gerbes A, Vargas V, Alessandria C, Bernardi M, Ginès P, Moreau R, Angeli P, Jalan R, Arroyo V; PREDICT STUDY group of the EASL-CLIF CONSORTIUM. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. J Hepatol. 2021 May;74(5):1097-1108. doi: 10.1016/j.jhep.2020.11.019. Epub 2020 Nov 20.
- Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, Giovo I, Uschner FE, Jimenez C, Mookerjee R, Gustot T, Albillos A, Banares R, Janicko M, Steib C, Reiberger T, Acevedo J, Gatti P, Bernal W, Zeuzem S, Zipprich A, Piano S, Berg T, Bruns T, Bendtsen F, Coenraad M, Merli M, Stauber R, Zoller H, Ramos JP, Sole C, Soriano G, de Gottardi A, Gronbaek H, Saliba F, Trautwein C, Ozdogan OC, Francque S, Ryder S, Nahon P, Romero-Gomez M, Van Vlierberghe H, Francoz C, Manns M, Garcia E, Tufoni M, Amoros A, Pavesi M, Sanchez C, Curto A, Pitarch C, Putignano A, Moreno E, Shawcross D, Aguilar F, Claria J, Ponzo P, Jansen C, Vitalis Z, Zaccherini G, Balogh B, Vargas V, Montagnese S, Alessandria C, Bernardi M, Gines P, Jalan R, Moreau R, Angeli P, Arroyo V; PREDICT STUDY group of the EASL-CLIF Consortium. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol. 2020 Oct;73(4):842-854. doi: 10.1016/j.jhep.2020.06.013. Epub 2020 Jul 13.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PREDICT (CardioDx)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.